Form 4: Replimune Insider Sells Shares for Tax Withholding

Konstantinos Xynos, Chief Medical Officer at Replimune Group, Inc., sold 14,023 shares of common stock to cover tax withholding obligations related to Restricted Stock Units.

Summary

• Konstantinos Xynos, Chief Medical Officer at Replimune Group, Inc., reported a transaction on May 18, 2026.
• The transaction involved the sale of 14,023 shares of common stock.
• These shares were sold to cover tax withholding obligations associated with the partial vesting of Restricted Stock Units (RSUs).
• The sale was executed under an irrevocable 'sell to cover' provision in the RSU award agreements, not as a discretionary sale.
• The weighted average sale price was $5.08 per share, with individual sales ranging from $5.01 to $5.08.
• Following this transaction, Mr. Xynos beneficially owns 235,662 shares of common stock.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a neutral to slightly negative filing due to the insider selling, despite the clear explanation of it being for tax purposes. The sale price range might also be a point of concern.

Positives

• The sale was conducted under a pre-arranged 'sell to cover' plan, indicating it was not a discretionary decision to divest shares based on market outlook.
• The transaction is a standard procedure for covering tax liabilities on vested equity awards.

Negatives

• An insider, the Chief Medical Officer, has sold a portion of their holdings, which could be perceived negatively by the market, despite the stated reason.
• The sale price of $5.01-$5.08 per share may indicate a lower valuation compared to previous periods or market expectations.

Risks

• Potential for negative market perception due to insider selling, even if for tax purposes.
• The weighted average sale price might reflect a downward trend in the stock's valuation.

Future Outlook

No specific future outlook or guidance is provided in this Form 4 filing, as it solely reports a past transaction.

Management Comments

• The transaction reported herein was made in accordance with the irrevocable 'sell to cover' provision set forth in the award agreements under which the RSUs were granted and does not represent a discretionary sale by the Reporting Person.

Industry Context

StockSavvy.ai notes that insider selling, even for tax purposes, can sometimes create short-term negative sentiment. However, the 'sell to cover' mechanism is a common and accepted practice for managing equity compensation tax liabilities within the biotechnology and pharmaceutical sectors, where equity awards are prevalent.

Stakeholder Impact

• Shareholders: May perceive insider selling negatively, potentially impacting short-term stock price, although the reason is tax-related.
• Employees: The transaction is a standard part of executive compensation and does not directly impact other employees.
• Management: The Chief Medical Officer is managing their tax obligations related to equity compensation.

Next Steps

• No specific next steps are outlined in this filing beyond the completion of the reported transaction.

Key Dates

Recommendation

This filing reports a routine transaction for tax withholding by an executive, not a strategic decision or a reflection of the company's fundamental performance. While insider selling can be a negative signal, the clear explanation of the 'sell to cover' mechanism mitigates significant concern. Investors should focus on the company's core business performance and pipeline updates for investment decisions.

Keywords

Replimune Group, REPL, Form 4, Insider Transaction, Stock Sale, Tax Withholding, Restricted Stock Units, Konstantinos Xynos, Chief Medical Officer, Beneficial Ownership